Q3 2024 Earnings Estimate for Mineralys Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:MLYS)

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Equities researchers at HC Wainwright dropped their Q3 2024 EPS estimates for shares of Mineralys Therapeutics in a note issued to investors on Wednesday, August 14th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($0.83) for the quarter, down from their prior forecast of ($0.72). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($2.92) per share. HC Wainwright also issued estimates for Mineralys Therapeutics’ Q4 2024 earnings at ($0.84) EPS, FY2024 earnings at ($3.22) EPS, FY2025 earnings at ($3.48) EPS, FY2026 earnings at ($3.08) EPS, FY2027 earnings at ($3.46) EPS and FY2028 earnings at ($1.79) EPS.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.10). During the same quarter in the prior year, the business posted ($0.31) EPS.

Mineralys Therapeutics Stock Up 0.5 %

MLYS stock opened at $9.81 on Friday. Mineralys Therapeutics has a 52-week low of $5.85 and a 52-week high of $16.91. The firm has a market cap of $487.06 million, a P/E ratio of -4.48 and a beta of 1.93. The company’s 50-day simple moving average is $12.35 and its 200-day simple moving average is $12.92.

Insider Buying and Selling

In other Mineralys Therapeutics news, Director Brian Taylor Slingsby sold 550,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 24th. The stock was sold at an average price of $13.05, for a total value of $7,177,500.00. Following the sale, the director now directly owns 8,644,579 shares of the company’s stock, valued at $112,811,755.95. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, Director Brian Taylor Slingsby sold 550,000 shares of the business’s stock in a transaction on Wednesday, July 24th. The shares were sold at an average price of $13.05, for a total value of $7,177,500.00. Following the completion of the sale, the director now owns 8,644,579 shares of the company’s stock, valued at approximately $112,811,755.95. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Adam Scott Levy sold 96,815 shares of the stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $12.94, for a total transaction of $1,252,786.10. Following the transaction, the chief financial officer now directly owns 255,462 shares in the company, valued at $3,305,678.28. The disclosure for this sale can be found here. In the last 90 days, insiders sold 706,679 shares of company stock valued at $9,204,818. 33.24% of the stock is owned by company insiders.

Institutional Investors Weigh In On Mineralys Therapeutics

Several large investors have recently bought and sold shares of MLYS. China Universal Asset Management Co. Ltd. lifted its position in shares of Mineralys Therapeutics by 67.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 7,931 shares of the company’s stock valued at $102,000 after acquiring an additional 3,181 shares in the last quarter. CWM LLC raised its stake in Mineralys Therapeutics by 120.0% in the 4th quarter. CWM LLC now owns 5,891 shares of the company’s stock valued at $51,000 after purchasing an additional 3,213 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in Mineralys Therapeutics by 17,821.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,122 shares of the company’s stock valued at $35,000 after purchasing an additional 4,099 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Mineralys Therapeutics by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 982,932 shares of the company’s stock valued at $12,690,000 after purchasing an additional 4,952 shares in the last quarter. Finally, Federated Hermes Inc. boosted its stake in Mineralys Therapeutics by 100.0% during the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock worth $140,000 after purchasing an additional 6,000 shares during the last quarter. 84.46% of the stock is currently owned by hedge funds and other institutional investors.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.